Streetbeat News

Products Services

GE

GE Vernova, a segment of GE, has signed a framework agreement with Forestalia to install up to 693 MW of onshore wind turbines in Aragon, Spain. The agreement includes 110 GE 6.1-158 turbines across 16 sites, with the first phase of 33 turbines already in progress. This deal extends GE's wind energy presence in Spain and contributes to the country's energy transition and decarbonization efforts. Deliveries are scheduled to be completed by the end of 2024, and the partnership also includes GE's first European PPA signed in 2022.

Portfolio Pulse from Benzinga Newsdesk

December 14, 2023 | 2:02 pm

GWRE

Guidewire Software, Inc. (GWRE) and Kanverse.ai have launched Kanverse's new accelerator for Submission Intake, now available in the Guidewire Marketplace for PolicyCenter users. This tool enables insurers to automate data filing, significantly reduce cycle times, lower operational costs, and increase productivity by focusing on strategic activities.

Portfolio Pulse from Benzinga Newsdesk

December 14, 2023 | 1:57 pm

AVGO

Broadcom Inc (NASDAQ:AVGO) stock reached an all-time high of $1,099.78, driven by strong Q4 earnings, AI sector growth, and strategic partnerships with companies like Google and Comcast. The company's AI infrastructure revenue is expected to grow from $4 billion in FY23 to $8 billion in FY24. Technical analysis shows a golden cross formation, and analysts rate AVGO as a buy with price targets between $1,000 and $1,160.

Portfolio Pulse from Surbhi Jain

December 14, 2023 | 1:56 pm

GKOS

The FDA has approved Glaukos Corporation's iDose TR, an eye implant for treating intraocular pressure in glaucoma patients. The approval is based on positive Phase 3 trial results. Glaukos plans to start commercial launch in early 2024 with a set price of $13,950 per dose. The company also reaffirmed its 2023 sales guidance and provided a preliminary 2024 sales guidance, which is above consensus estimates. GKOS shares rose 7.58% in premarket trading.

Portfolio Pulse from Vandana Singh

December 14, 2023 | 1:53 pm

GKOS

Glaukos Corporation's stock is trading higher following the announcement of FDA approval for its iDose TR product. The company also provided preliminary net sales guidance for 2024 that exceeded analyst estimates.

Portfolio Pulse from Benzinga Newsdesk

December 14, 2023 | 1:52 pm

NEOG

Neogen Corporation has entered into a collaboration with The Cat Fanciers' Association (CFA) to enhance the genomic products offered to CFA members. The partnership will focus on marketing, education, and promotion of Neogen's technology and products to advance the health, breeding, and care of cats.

Portfolio Pulse from Benzinga Newsdesk

December 14, 2023 | 1:50 pm

APLS

Apellis Pharmaceuticals shares are trading lower following the company's announcement that it received a negative trend vote on the marketing authorization application for its drug pegcetacoplan. This vote is a setback for the company as it suggests that the marketing authorization for pegcetacoplan may not be granted, which could impact the company's revenue and growth prospects.

Portfolio Pulse from Benzinga Newsdesk

December 14, 2023 | 1:48 pm

AXP

CI

HUM

LLY

OILK

On CNBC's 'Halftime Report Final Trades,' Sarat Sethi recommended American Express (AXP) due to expected increased spending from millennials. American Express CEO noted strong demand for premium cards. Bryn Talkington suggested ProShares K-1 Free Crude Oil Strategy ETF (OILK) as her final trade. Stephen Weiss chose Humana (HUM) after Cigna (CI) ended acquisition talks over price disagreements. Joseph Terranova favored Eli Lilly (LLY) as it continues to rise following positive study results for Zepbound. Stock prices for HUM, AXP, LLY, and OILK all saw gains in the last session.

Portfolio Pulse from Avi Kapoor

December 14, 2023 | 1:48 pm

ENSC

ESPR

MRNA

Esperion Therapeutics announced that the FDA updated the LDL-C lowering indication for its drugs NEXLETOL and NEXLIZET, causing ESPR shares to surge by 46%. Ensysce Biosciences released a study showing efficacy data for its drug PF614, leading to a 62% jump in ENSC shares. Moderna's stock rose by 12% after announcing positive follow-up data from a Phase 2b study of mRNA-4157-P201 in partnership with Merck for treating high-risk melanoma.

Portfolio Pulse from ryanfaloona@benzinga.com

December 14, 2023 | 1:47 pm

DGLY

Digital Ally, Inc. (NASDAQ:DGLY) announced that its deferred revenue has surpassed $10 million, marking a significant milestone for the company. This achievement is attributed to the strong demand for its FirstVu Pro body-worn cameras and EVO-HD in-car video solution, offered through a subscription payment plan. The plan, introduced in mid-2020, has been successful and well-received in the industry, particularly by municipalities with limited funding. The company's President, Brody Green, expressed confidence in continued growth and market share expansion. Digital Ally also filed an S-4/A Registration Statement Amendment with the SEC and announced new law enforcement orders, patents, and the addition of the InterVu Room solution to its product lineup.

Portfolio Pulse from Benzinga Newsdesk

December 14, 2023 | 1:46 pm